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There is a large body of evidence data regarding the benefit of supersaturated calcium phosphate solution (SCPS) in
treatment of oral mucositis in haematology malignances, after bone marrow transplantation3. For patients treated with
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 Unicentric, prospective, non randomized clinical study with an unblinded sample of allocation for convenience.
 2 arms: Experimental arm with SCPS vs Control arm with mouthwash of lidocaine and bicarbonate (LB).
 Both arms received prophilactic nystatin mouthwash.
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PREVENTION AND TREATMENT OF ORAL MUCOSITIS IN PATIENTS TREATED 
WITH CHEMORADIOTHERAPY WITH HEAD AND NECK CANCER
CONCLUSIONS
PURPOSE
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Table 1. Physicians and nurse consults before mucositis diagnosed, both arms.   
Table 2. Once weekly physicians consult and dayly nurse consults to patients, both arms, when mucositis diagnosed
ELEGIBILITY CRITERIA
Pathologic proven squamous cell carcinoma HNC
Stage III and IVa
Concomitant CRT
No previous chemotherapy
IMRT, 60 to 69,96 Gy.
Cisplatin (100mg/m2), 3 Cicles
Patients with competence for selfcare
Informed consent form for each patient
EVALUATION CRITERIA
TIME TO  MUCOSITIS G≥1- PREVENTION CRITERIA
REDUCTION AT LEAST ONE GRADE OF MUCOSITIS DURING QRT AND 4 WEEKS AFTER QRT-
TREATMENT CRITERIA
Fig.1 Clinical Study Design
2 groups, control arn and study arm, and the posology used for prevention and treatment, according to the grade of mucositis.
Nistatin: prevention of fungal infection, in both arms.




3 times per day
Study arm





6 times per day
Study arm
6 times per day 
Control arm 
8 times per day
Study arm
8 times per day 
Both groups with Nistatin
To evaluate the mucositis it was used the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
For statistical analysis it was used the following tests:Willcoxon-Man Withney, Fisher, Logrank and Pearson.
Due to logistic reasons this was a non-randomized and an unblinded study; however, SFCS was superior to
mouthwash LB on prophylactic and treatment of mucositis in patients with HNC.
We also conclude the importance of nurse care assistance in these preventions, optimizing a better selfcare



















Reduction at least one
grade of mucositis 4 



















(Mín – Máx) 3 (2-6) 4 (2-6) 0.046
Tables 4, 5 and 6.  Prevention and treatment of mucositis, in both arms
Superiority of SCPS for treatment with a very statistic p value.
Note: table 6, study arm with 16 patients because one of them don't change the grade of mucositis, 4 weeks after CRT.
There were no statistic differences in tube feeding, use of morfine or inward, in both arms.





Age, years Median (Mín – Max) 56 (17-67) 61 (38-68) 0.101


















































Number of cicles of
Cisplatin
Median (Mín – Máx) 3 (2-3) 3 (2-3) 0.426
Table 3. General informations, both arms.
1. CTCAE, V.4,0; 2. NCCN guidelines for Head and Neck 2014 3. Markievicz, et al. Treating oral mucositis with a supersaturated calcium





INWARD DUE TO MUCOSITIS
